Fit, busy, family history of Alzheimer's
Daniel is 41, a lawyer in Manhattan, and sleeps about six hours on a good night. He asked about Alzheimer's at his welcome call because his grandmother had it. His last physical came back with the line most people get: "Everything looks fine." Homocysteine and omega-3 weren't checked at all.

Daniel, 41
- Vitamin B12380 pg/mL
- Blood pressure126/82
Not on a typical panel
- Homocysteine14.5 µmol/L
- APOEε4/ε4
- Omega-34.2%
- Alzheimer's PRS58th pct
- Sleep, 30-day avg6h 05m
Odds of Alzheimer's disease relative to the ε3/ε3 genotype
Two readings of the same number
Standard Target< 15
14.5µmol/L
Lab report flags nothing.
“Homocysteine looks fine”
Homocysteine is linked to Alzheimer's, especially for ε4 carriers
Independent of APOE carrier status, homocysteine above 14 nearly doubled the risk of Alzheimer's disease, and each 5 µmol/L higher raised it by about 40%.3 For ε4 carriers specifically, those in the highest homocysteine quartile had 51% higher odds of cognitive dysfunction than carriers in the lowest.4
A tighter target for two copies of ε4
Clear next steps
Daniel's SONATA doctor walks him through the plan, explains his genetic risk and what his biomarkers mean, and prescribes what he needs.
Priority 1
B vitamins and omega-3, together
Priority 2
Sleep and exercise
Ongoing
A care plan that evolves with him
- At six months, he retests homocysteine, omega-3 and B12 to see whether the supplements are working.
- His SONATA doctor may recommend a p-tau217 blood test. It measures a protein that rises years before symptoms, giving him a baseline to track and the chance to intervene early.13
Found at 41, two decades before symptoms typically begin
With SONATA, Daniel brings homocysteine below 8, sleeps seven hours, and exercises most days. Physically active ε4 carriers showed cognitive trajectories similar to active non-carriers over 18 months, while sedentary carriers declined fastest.11

40%
of dementia worldwide is attributable to 12 modifiable risk factors
Livingston et al., Lancet 202012

